Bioenvision's Suvus(TM) Lowers Viral Load In Chronic Hepatitis C; Randomized Study Data Presented At Scientific Conference

NEW YORK--(BUSINESS WIRE)--Sept. 8, 2006--Bioenvision, Inc. (NasdaqGM:BIVN) today announced results of a randomized Phase II trial of Suvus(TM) in patients with chronic hepatitis C virus infection (HCV). The data was presented at the British Association for the Study of the Liver's annual meeting in Dublin.

Back to news